Brought to you by 
Vivelix licenses first candidate; gets global rights to Idera's IMO9200; Deal terminated
07 Jun 2022
Executive Summary
Idera Pharmaceuticals Inc. licensed eight-month-old Vivelix Pharmaceuticals Ltd. exclusive worldwide rights (including rights to sublicense) to develop and market IMO9200 for non-malignant gastrointestinal disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vivelix licenses first candidate; gets global rights to Idera's IMO9200; Deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice